AJOVY (fremanezumab) demonstrates clinically significant reductions in headache and migraine-related disability in the majority of patients studied. The treatment achieves downward shifts in disability severity and improves HIT-6 and MIDAS scores, particularly for patients with difficult-to-treat migraine.
Researchers in 16 countries explore nutritional care for recovering COVID-19 patients; Nutricia donates medical products to support their recovery. Dr. Riccardo Caccialanza highlights the need for clinical guidance to optimize patient recovery and regain daily functioning.
A study reveals that less than half of European osteoporosis patients take both calcium and vitamin D supplements with their treatment. The majority claim to miss doses due to lack of understanding or inadequate physician guidance. Improved patient education is crucial to maximize the benefits of combination therapy.
The LEADERS study demonstrated that Biosensors DES is non-inferior to Cypher DES in terms of clinical events, stent thrombosis rates and angiographic follow-up data. The trial included a broad range of patients with symptomatic coronary disease, reflecting routine clinical practice.
New studies presented at the XVII International AIDS Conference confirm a clear threshold response for DNA damage caused by ethyl methanesulfonate (EMS) in Viracept. The research finds that patients exposed to elevated EMS levels are not at increased risk of cancer, despite levels below this threshold.
The presence of an impurity called ethyl methanesulfonate (EMS) in Roche's Viracept HIV medication did not increase patients' risk of developing cancer, according to new research confirmed by the European Committee for Human Medicinal Products (CHMP).
A global study found significant differences in the standard of care for osteoporosis across Europe, North America, and Australia. Women in Europe reported lower use of bone-saving drugs and fewer bone density tests than those in other regions, highlighting the need for improved regional comparisons.
New study results demonstrate significant relief of IBS-C symptoms in adult women treated with AMITIZA 8 mcg, improving overall quality of life. This approval marks a significant advancement in treating IBS-C, which affects approximately one-third of IBS cases.
A new study presented at AARC found that ramelteon did not exacerbate respiratory depressant effects in patients with moderate to severe chronic obstructive pulmonary disease (COPD). The study showed significant increases in total sleep time and sleep efficiency with ramelteon compared to placebo.
Tamiflu significantly reduces illness severity and duration in children one year and older, with a 29% reduction in influenza severity and 26% reduction in illness duration compared to placebo. The new lower dose capsules offer a convenient alternative for the treatment and prevention of influenza types A and B.
The report warns that inadequate pandemic planning, including poor on-the-ground administration and delivery of antivirals and vaccines, could threaten EU security. The survey found that few countries have defined plans for distribution of antivirals or specific guidance on vaccine storage and administration.
New research supports the cardiovascular safety of ACTOS (pioglitazone HCI) and its benefits in improving blood glucose and lipid levels. The study found that therapies including pioglitazone are associated with significant reductions in the risk of stroke or myocardial infarction compared to non-thiazolidinedione therapies.
A study predicts that using Tamiflu prophylactically could reduce illness and death rates during an influenza pandemic by half, with a cost savings of $70,000 per 1,000 population. Prophylaxis with antivirals or vaccines is considered a crucial strategy in the early months of a pandemic.
Studies demonstrated that ROZEREM did not impair middle-of-the-night balance, mobility or memory performance in patients with chronic insomnia. The medication's unique mechanism of action targets the suprachiasmatic nucleus, which regulates the sleep-wake cycle, and showed no evidence of abuse potential.
A new study has shown that long-term biologic treatment can significantly reduce disability in patients with rheumatoid arthritis, while maintaining a safe and effective profile. The analysis of over 2,000 patients demonstrates improvements in disability whilst safety was also sustained over the long-term.
A new study presented at the American Psychiatric Association 2007 Annual Meeting found that ramelteon did not impair middle-of-the-night balance, mobility, or memory performance in older adults with insomnia. The study also demonstrated that patients treated with zolpidem had impaired performances on these measures.
A new study has shown that lubiprostone can improve symptom relief rates in adults with irritable bowel syndrome with constipation (IBS-C) by nearly twice as much as those receiving placebo, according to the results presented at Digestive Disease Week 2007.
A retrospective analysis found patients taking risedronate (Actonel) had a lower incidence of hip fractures compared to those taking alendronate. The REAL study used a health service utilization database and provided valuable insights into the clinical effectiveness of these osteoporosis treatments.
A powerful analysis reveals that only one-third of high-risk populations in Europe receive seasonal influenza vaccine, resulting in avoidable morbidity and mortality. Implementing EU vaccination recommendations could reduce the number of cases of death and illness from influenza, as well as contribute to flu pandemic preparedness.
A retrospective study of 33,000 women with osteoporosis found that Actonel significantly reduced the risk of hip fractures compared to alendronate. The results showed a 46% lower incidence of hip fractures at six months and a 43% reduction at 12 months.
A new clinical trial, CHICAGO, demonstrated that pioglitazone (ACTOS) reduced the progression of carotid intima-media thickness (CIMT), a surrogate marker for heart attack and stroke, by 0.013 mm. The study also showed improved glycemic control, decreased triglycerides, and increased HDL-C levels with ACTOS treatment.
A new study indicates that boosted Invirase results in comparable levels of viral suppression as lopinavir, while also reducing the risk of elevated cholesterol and triglycerides. The treatment also showed fewer gastrointestinal adverse events compared to lopinavir.
The study demonstrated that AMITIZA increased fluid secretion in the intestine, improving symptoms of chronic idiopathic constipation. Patients experienced significant improvements in constipation severity and abdominal bloating and discomfort for up to 12 months.
In a Phase III trial, AMITIZA demonstrated significant improvements in chronic constipation symptoms, including reduced straining, bloating, and discomfort. The study showed efficacy across IBS-C and non-IBS-C patients, with fewer adverse events reported in the placebo group.
New data reinforce the safety profile of ENBREL, confirming its efficacy for up to 2.5 years with no significant increase in adverse events. The study also shows that patients who experience interruption in treatment can regain similar positive efficacy results after re-initiating therapy.
ACTOS demonstrated significant improvements in reducing the risk of heart attacks, strokes, and cardiovascular death in high-risk patients with type 2 diabetes. The study showed a 23% reduction in heart attacks and an 18% reduction in combined risk of cardiovascular death, nonfatal heart attack, or nonfatal stroke.
New analyses of the PROactive Study found that ACTOS (pioglitazone HCl) significantly reduced the risk of recurrent stroke in high-risk patients with type 2 diabetes, with a 47% reduction in incidence and a 28% decrease in combined risk of death, MI, or stroke.
The International AIDS Society guidelines recommend treating HIV patients with an undetectable viral load using a combination of FUZEON and protease inhibitors. This approach is supported by recent clinical trials and has been endorsed by various health organizations, aiming to combat drug resistance and improve treatment outcomes.
The SYMPHONY study revealed that a CellCept-based drug combination, including low-dose tacrolimus and corticosteroids, significantly improved kidney function and reduced early rejection rates. This regimen is expected to prolong the life of both patients and their transplanted organs.
The launch of Tygacil (tigecycline) in the UK marks a significant step forward in the fight against antibiotic-resistant bacteria, including MRSA and Escherichia Coli. The new antibiotic has been developed to overcome common mechanisms of resistance and offers a single effective therapy for complicated skin and soft tissue infections.
The TEMPO extension trial found that adding Enbrel to methotrexate improved clinical remission rates, reduced disease activity, and enhanced quality of life among patients with rheumatoid arthritis. The study showed significant benefits in patients who had not achieved adequate response with methotrexate monotherapy.
A study found that ROZEREM was effective in promoting sleep and did not cause lingering effects the next day. The medication was associated with a decrease in time to fall asleep compared to placebo.
The study found that ACTOS reduced the number of patients on insulin and mean daily insulin dose, as well as delaying need for permanent insulin use. In high-risk patients with type 2 diabetes, these results could lead to less dependence on daily insulin use.
The CHICAGO trial will examine ACTOS' effect on blood vessel health and atherosclerosis, beyond glycemic control. The 18-month study aims to gather further information about the management of cardiovascular disease in people with type 2 diabetes.
Phase 3 clinical trials demonstrate desvenlafaxine succinate's effectiveness in reducing depressive symptoms and improving quality of life for adult patients. The medication also showed promise in managing depression-related pain, highlighting its potential as a valuable treatment option.
A new study found that Enablex, a prescription medication for overactive bladder (OAB), did not cause significant memory impairment in healthy adults aged 60 and older. In contrast, the alternative treatment Ditropan XL caused noticeable memory deterioration, despite the patients being unaware of this change.
A study of patients over 65 showed that AMITIZA significantly increased spontaneous bowel movements, improving symptoms of chronic idiopathic constipation. The medication was well-tolerated, with fewer adverse events compared to placebo, and is approved for use in adults regardless of age or gender.
Researchers found that patients taking ramelteon experienced a significant advancement of dim light melatonin secretion offset compared to placebo. The results suggest that ramelteon may help people adjust to time zone changes and shift their natural circadian rhythm.
A recent study found that AMITIZA improved symptoms of irritable bowel syndrome with constipation (IBS-C), including abdominal pain and bloating. The treatment was associated with significant improvements in patients' quality of life.
A study found that ramelteon significantly reduced time to fall asleep in approximately two-thirds of patients, with no rebound insomnia or withdrawal effects. The medication showed effectiveness in treating chronic insomnia, representing an alternative option for patients seeking a safe sleeping aid.
Ferriprox has been shown to provide significantly better cardio-protection compared to deferoxamine, reducing heart iron concentrations and improving cardiac function in thalassemia patients. The study findings suggest that Ferriprox's small structure provides a greater potential to chelate intracellular iron in the heart.
A European study found pramipexole significantly reduces RLS severity and improves quality of life, with notable improvements in Vitality and Bodily Pain scores. The treatment showed efficacy using two measurement criteria: IRLS and CGI-I scale.
A clinical trial found that patients with RLS who continued treatment with pramipexole experienced a significantly longer time before symptoms worsened compared to those on placebo. Pramipexole also improved quality of life scores, demonstrating its potential as a long-term treatment option for RLS.
Researchers found that MMF was superior to traditional treatment in inducing complete remission and had fewer severe side effects. The new findings offer hope for improving quality of life for millions of people worldwide suffering from lupus.
A new study published in the New England Journal of Medicine suggests that CellCept, a potential treatment for lupus nephritis, holds promise for improving quality of life for those affected by severe kidney disease. The results offer hope for patients who currently suffer debilitating side effects from traditional treatments.
A recent study found that 76% of treatment-experienced patients would consider using a self-injectable HIV therapy if recommended by their physician. Despite this, only one quarter of eligible patients have discussed the option with their doctors, highlighting a significant barrier to adoption.
The PROactive study shows ACTOS significantly reduced the recurrence of heart attacks and acute coronary syndrome in high-risk patients with type 2 diabetes. The medication demonstrated a 28 percent reduction in fatal or non-fatal heart attacks, as well as a 37 percent risk reduction in acute coronary syndrome.
A recent Gallup survey found that 53% of adults with sleep problems are not receiving treatment, while 77% express concerns about long-term effects of prescription sleep aids. Worry is a common factor interfering with nearly 40% of older adults' ability to fall asleep, especially among primary caregivers.
The PRECiSE 2 study found that patients treated with CIMZIA achieved a higher clinical response and remission rate compared to those receiving placebo. The study demonstrated the efficacy of CIMZIA in maintaining clinical response after induction therapy, with a significant proportion of patients able to achieve remission by week 26.
The HERA study found that Herceptin reduces the risk of cancer coming back by 52% and death by 33% in early-stage HER2-positive breast cancer. The results provide new hope for women with this aggressive form of breast cancer, offering improved survival rates.